495 related articles for article (PubMed ID: 37247488)
1. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
[TBL] [Abstract][Full Text] [Related]
2. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
3. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
4. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
[TBL] [Abstract][Full Text] [Related]
6. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
7. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
8. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.
Etemadifar M; Sedaghat N; Nouri H; Lotfi N; Chitsaz A; Khorvash R; Zolfaghari H; Ghasemi Movaghar A; Pourabbas M; Salari M
Mult Scler Relat Disord; 2022 Jan; 57():103417. PubMed ID: 34875487
[TBL] [Abstract][Full Text] [Related]
10. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
11. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E
Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
[TBL] [Abstract][Full Text] [Related]
13. Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.
Drulovic J; Ivanovic J; Martinovic V; Tamas O; Veselinovic N; Cujic D; Gnjatovic M; Mesaros S; Pekmezovic T
Mult Scler Relat Disord; 2021 Sep; 54():103150. PubMed ID: 34298478
[TBL] [Abstract][Full Text] [Related]
14. Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.
Sedaghat N; Etemadifar M; Lotfi N; Sayahi F; Chitsaz A; Salari M; Ghasemi Movaghar A
Front Immunol; 2023; 14():952911. PubMed ID: 36895555
[TBL] [Abstract][Full Text] [Related]
15. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
König M; Lorentzen ÅR; Torgauten HM; Tran TT; Schikora-Rustad S; Vaage EB; Mygland Å; Wergeland S; Aarseth J; Aaberge IAS; Torkildsen Ø; Holmøy T; Berge T; Myhr KM; Harbo HF; Andersen JT; Munthe LA; Søraas A; Celius EG; Vaage JT; Lund-Johansen F; Nygaard GO
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):19-22. PubMed ID: 34670844
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
Habek M; Jakob Brecl G; Bašić Kes V; Rogić D; Barun B; Gabelić T; Emeršič A; Horvat Ledinek A; Grbić N; Lapić I; Šegulja D; Đurić K; Adamec I; Krbot Skorić M
J Neuroimmunol; 2021 Oct; 359():577696. PubMed ID: 34418815
[TBL] [Abstract][Full Text] [Related]
18. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
[TBL] [Abstract][Full Text] [Related]
19. Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.
Ozdede A; Nohut OK; Atli Z; Tok YT; Guner S; Yilmaz E; Ucar D; Uygunoglu U; Hamuryudan V; Seyahi E
Rheumatol Int; 2022 Oct; 42(10):1741-1750. PubMed ID: 35779083
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
